Published in PLoS One on May 11, 2015
HMDB 3.0--The Human Metabolome Database in 2013. Nucleic Acids Res (2012) 9.21
Epithelial cells as sensors for microbial infection. J Clin Invest (1997) 3.47
Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health (2012) 3.01
The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem (1996) 2.88
The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol (2010) 2.74
Inflammatory mediators of asthma: an update. Pharmacol Rev (1998) 2.54
Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem (1992) 2.20
Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology (1995) 2.12
Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost (1999) 2.07
Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest (2002) 1.91
Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci (2012) 1.79
Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol (2002) 1.70
Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J Biol Chem (2004) 1.69
Expression of the potent inflammatory cytokines, granulocyte-macrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma. J Allergy Clin Immunol (1992) 1.68
Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol (1995) 1.67
Crystal structure of thrombin bound to heparin. J Biol Chem (2004) 1.61
Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med (2006) 1.58
Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. JAMA Surg (2014) 1.51
Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol (1999) 1.34
Role of interleukin-8 in neutrophil signaling. Curr Opin Hematol (2000) 1.27
Induction of IL-8 production in human alveolar macrophages and human bronchial epithelial cells in vitro by swine dust. Thorax (1998) 1.26
Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases. Am J Respir Cell Mol Biol (2003) 1.25
The potential of biologics for the treatment of asthma. Nat Rev Drug Discov (2012) 1.11
Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology (1999) 1.09
Dual role of Toll-like receptors in asthma and chronic obstructive pulmonary disease. Pharmacol Rev (2012) 1.02
Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem (1986) 1.01
The expression of heparin-binding epidermal growth factor-like growth factor by regulatory macrophages. J Immunol (2009) 1.00
Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein. Implications in biological activity. J Biol Chem (1997) 0.99
Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol (1995) 0.99
Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2. Glycobiology (1994) 0.98
Immunotoxicity of monoclonal antibodies. MAbs (2009) 0.97
Effects on molecular conformation and anticoagulant activities of 1,6-anhydrosugars at the reducing terminal of antithrombin-binding octasaccharides isolated from low-molecular-weight heparin enoxaparin. J Med Chem (2010) 0.96
Asthma: beyond corticosteroid treatment. Arch Med Sci (2013) 0.95
Tunable heparan sulfate mimetics for modulating chemokine activity. J Am Chem Soc (2013) 0.94
Heparin and heparan sulfate bind interleukin-10 and modulate its activity. Blood (2000) 0.94
Monocyte cell surface glycosaminoglycans positively modulate IL-4-induced differentiation toward dendritic cells. J Immunol (2008) 0.93
The solution structure of the N-terminal domain of hepatocyte growth factor reveals a potential heparin-binding site. Structure (1998) 0.92
Capillary electrophoresis for the analysis of glycosaminoglycans and glycosaminoglycan-derived oligosaccharides. Biomed Chromatogr (2002) 0.90
Heparin-induced leukocytosis requires 6-O-sulfation and is caused by blockade of selectin- and CXCL12 protein-mediated leukocyte trafficking in mice. J Biol Chem (2011) 0.88
A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins. J Pharm Biomed Anal (2007) 0.88
Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med (1999) 0.87
Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin. J Pharm Sci (2009) 0.86
Inhibitory effects of low molecular weight heparin on mediator release by mast cells: preferential inhibition of cytokine production and mast cell-dependent cutaneous inflammation. Clin Exp Immunol (1997) 0.86
Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci (2001) 0.86
Effective reversed-phase ion pair high-performance liquid chromatography method for the separation and characterization of intact low-molecular-weight heparins. Anal Biochem (2009) 0.85
Heparin and structurally related polymers attenuate eotaxin-1 (CCL11) release from human airway smooth muscle. Br J Pharmacol (2008) 0.85
Bioactivity screening of partially desulfated low-molecular-weight heparins: a structure/activity relationship study. Glycobiology (2011) 0.84
Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle. Br J Pharmacol (2005) 0.84
Non-anticoagulant derivatives of heparin for the management of asthma: distant dream or close reality? Expert Opin Investig Drugs (2014) 0.81
Size-fractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol (2007) 0.81
Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics. PLoS One (2015) 0.81
Ion exchange chromatographic separation and isolation of oligosaccharides of intact low-molecular-weight heparin for the determination of their anticoagulant and anti-inflammatory properties. Anal Bioanal Chem (2013) 0.80
Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther (2006) 0.79
Low-molecular-weight heparins: differential characterization/physical characterization. Handb Exp Pharmacol (2012) 0.78
Investigation of freezing- and thawing-induced biological, chemical, and physical changes to enoxaparin solution. J Pharm Sci (2009) 0.78
The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin. Biochem J (1992) 0.78
Massive haemorrhage induced by low molecular weight heparin in a patient with steroid refractory ulcerative colitis. Scand J Gastroenterol (2004) 0.77
Low-molecular-weight heparin and unfractionated heparin decrease Th-1, 2, and 17 expressions. PLoS One (2014) 0.76
Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory Responses. PLoS One (2015) 0.77
Non-Anticoagulant Fractions of Enoxaparin Suppress Inflammatory Cytokine Release from Peripheral Blood Mononuclear Cells of Allergic Asthmatic Individuals. PLoS One (2015) 0.75